Epkinly Clinical Pearl

(8:41)

myTRIAList Clinical Trial: EPCORE NHL-6

(5:9)

Epkinly (epcoritamab-bysp)- refractory diffuse large B-cell lymphoma (DLBCL)

(1:53)

New DLBCL Clinical Trial: Epcoritamab for Diffuse Large B-Cell Lymphoma

(1:9)

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL

(1:49)

Subcutaneous epcoritamab in R/R B-cell NHL

(2:42)

Exploring the Approval of Epcoritamab for Diffuse Large B-Cell Lymphoma With Reid Merryman, MD

(5:57)

Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma

(2:30)

Dr Nowakowski on the FDA Approval of Epcoritamab in R/R Follicular Lymphoma

(1:6)

FDA D.I.S.C.O. Burst Edition: FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refracto...

(3:31)

Epcoritamab (Epkinly), a novel bispecific antibody to target cancer cells

(3:32)

Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD

(5:36)

Subcutaneous epcoritamab in R/R B-cell non-Hodgkin lymphoma

(9:41)

Results of Phase I/II study of epcoritamab+R-DHAX/C in patients with R/R DLBCL eligible for autoSCT

(2:42)

How to use Epkinly 48 Mg/0.8 Ml Subcutaneous Solution Antineoplastic - Immunotherapy, T-Cell Engage

(6:19)

EPCORE NHL-1 subgroup analyses: epcoritamab monotherapy in patients with R/R LBCL

(1:46)

Epcoritamab + R-CHOP overcomes high total metabolic tumor volume in high-risk large B-cell lymphoma

(36)

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma

(3:2)

Epkinly (Epcoritamab) how to use: Uses, Dosage, Side Effects, Contraindications

(4:7)